Raymond James & Associates Zentalis Pharmaceuticals, Inc. Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 12,113 shares of ZNTL stock, worth $49,542. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,113Holding current value
$49,542% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ZNTL
# of Institutions
142Shares Held
76.3MCall Options Held
68.2KPut Options Held
2.3K-
Matrix Capital Management Company, LP Waltham, MA14MShares$57.1 Million2.04% of portfolio
-
Eventide Asset Management, LLC Boston, MA11.6MShares$47.3 Million2.94% of portfolio
-
Black Rock Inc. New York, NY4.65MShares$19 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.4MShares$18 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.85MShares$15.8 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $233M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...